Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Mithridion, Inc. Announces New Funding and Outlines Strategy for Central Nervous System Drug Development

January 11, 2011 By Bio-Medicine.Org

MADISON, Wis. and TOLEDO, Ohio, Jan. 11, 2011 /PRNewswire/ —
Mithridion, Inc., a privately-owned clinical stage drug development
company focusing on serious Central Nervous System disorders,
including Alzheimer’s disease, announces that it has secured
commitments of $1.25 million in new funding.  

Venture Investors (VI – Madison, Wis.), The State of
Wisconsin Investment Board (SWIB – Madison, Wis.), and Rocket
Venture Fund (Toledo, Ohio) participated in the latest funding.

“We plan to use this new funding to explore additional niche
disease targets for MCD-386CR, our lead clinical drug candidate,
which is a new strategy for the company, to seek partners for our
drug candidates MCD-386CR and MI-10-022 for Alzheimer’s disease
(AD)  and schizophrenia, and to augment our science advisory
board and board of directors,” said Trevor M. Twose, Ph.D., the
company’s Chief Executive. “We greatly appreciate the continued
confidence of our shareholders,” he added.

Mithridion intends to develop its drug candidates for AD and
schizophrenia in partnership with pharmaceutical or
biopharmaceutical companies with the technical, manufacturing and
commercial resources to address these major market opportunities.
 

As a new part of its strategy, Mithridion is actively exploring
opportunities to develop its drug candidates in niche market
opportunities in serious CNS disorders.  Several promising
disease targets have been identified and are currently being
evaluated.  The company believes that it will be able to
create additional high value and strong entry barriers through this
strategy, which it intends to fund using a combination of equity
capital and non-dilutive funding.

MCD-386CR, a clinical-stage drug candidate with an open IND, has
“first-in-class” potential for improving memory and cognition in
AD, for improving cognition in schizophrenia, and for
disease-modifying effects (or stopping disease progressio

‘/>”/>

SOURCE

Related Articles Read More >

DeepWell Digital Therapeutics Mike Wilson Ryan Douglas
How DeepWell is developing video games as tools for treating medical conditions
A woman with a small, handheld device in her lap with tubes that look like earphones plugged into her ears.
Ear-puffing device for migraine treatment wins FDA breakthrough designation
Abbott
Abbott launches upgraded digital health app for neurostimulation
Catheter delivery could enable better brain implants: Synchron’s neuroscience chief explains how

DeviceTalks Weekly.

May 27, 2022
Quick message - No DTW podcast, but plenty else to listen to over this weekend and next week.
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech